Synthesis, Characterization, and Biological Activity of Tris(pentafluorophenyl)arsenic(V) Derivatives 187
REFERENCES
L′
C6F5
[1] Fild, M.; Glemser, O. In Fluorine Chemistry Reviews;
Tarrant, P. (Ed.); Marcel Dekkar: New York, 1969;
As
C6F5
Vol. 3, pp. 129–144.
[2] Raj, P.; Saxena, A. K.; Singhal, K.; Ranjan, A. Polyhe-
dron 1985, 42, 251–258.
[3] Otero, A.; Royo, P. J Organomet Chem 1978, 149,
315–320.
C6F5
L
[4] Siddiqui, R. A.; Raj, P.; Saxena, A. K.; Dixit, S. K.
FIGURE 1 Configuration of pentafluorophenylarsenic (V)
carboxylates. L = Lꢁ
=
OCOC6H4(o-OH) 1; OCOC-
Synth React Inorg Met-Org Chem 1996, 26(7), 1189–
1203.
[5] Saxena, A. K.; Ranjan, A.; Mishra, K.; Venkatara-
mani, P. S. Ind J Chem 1998, 37A, 736–738.
[6] Singhal, K.; Yadav, R. N. P.; Raj, P.; Agarwal, A. K.
J Fluorine Chem 2003, 121, 131–134.
(OH)(C6H5)2 2; and 2-(6-OCH3C10H6)CH(CH3)COO 3.
Lꢁ = Cl; L = OCOC6H4(o-OH) 4; OCOC(OH) (C6H5)2
5 and 2-(6-OCH3C10H6)CH(CH3)COO 6.
[7] Singhal, K.; Kant, R.; Raj, P.; Goswami, A. K. J Fluo-
rine Chem 2003, 122, 229–232.
[8] Singhal, K.; Rastogi, R.; Raj, P. Ind J Chem 1987, 26A,
146–150.
[9] Chandrasheka, K.; Behl, H. M.; Kumar, V.; Sidhu,
O. P.; Pushpangadan, P.; Rao, C. V.; Shukla, S. K.;
Ranjan, A.; Saxena, A. K.; Kant, R.; Singhal, K.; Raj,
P. PCT Patent Application WO 067800, 2006.
[10] Nevett, B. A.; Perry, A. Spectrochim Acta 1975, 31A,
101–106.
O
C6F5
R
C6F5
O
O
C6F5
C6F5
As
O
As
R
C6F5
C6F5
[11] Shukla, S. K.; Ranjan, A.; Saxena, A. K. Synth React
Inorg Met-Org Chem 2000, 30(5), 909–919.
[12] Otero, A.; Royo, P. J Organomet Chem 1978, 154,
13–19.
O
(R′ = C H 7, p-CF C H 8 and p-OCH C H 9)
R = –CH
6
5
3
6
4
3 6 4
C–
R′
[13] Goel, R. G.; Ridley, D. R. J Organomet Chem 1974,
13, 1252–1255.
[14] Li, J. S.; Ma, Y. Q.; Cui, J. R.; Wang, R. Q. Appl
Organomet Chem 2001, 15, 639–645.
FIGURE
2 Alternative square-pyramidal and trigonal-
bipyramidal arrangements of pentafluorophenylarsenic(V)
carboxylates.
[15] Gibbons, M. N.; Sowerby, D. B. J Organomet Chem
1998, 555, 271–278.
[16] Yu, L.; Ma, Y. Q.; Wang, G. C.; Li, J. S. Hetroatom
Chem 2004, 15(1), 32–36.
[17] (a) Saxena, A. K.; Ranjan, A.; Venkataramani, P. S.
Ind J Chem 1994, 33A, 948–951; (b) J Fluorine Chem
1993, 64, 107–115.
[18] Shukla, S. K.; Ranjan, A.; Saxena, A. K. J Fluorine
Chem 2002, 113, 155–159.
[19] Barucki, H.; Coles, S. J.; Costello, J. F.; Gelbrich, T.;
Hursthouse, M. B. J Chem Soc Dalton Trans 2000,
2319–2325.
[20] Barucki, H.; Coles, S. J.; Costello, J. F.; Hursthouse,
M. B. J Organomet Chem 2001, 622, 265–273.
[21] Shepard, W. A.; Sharts, C. M. Organic Fluorine
Chemistry; W. A. Benjamin, Inc.: New York, 1969,
pp. 33–40.
the results obtained, it can be inferred that the car-
boxylate moieties that are themselves biologically ac-
tive do not display significant activity in combination
with (C6F5)3As. The variation in biological activity of
these compounds is affected because of the varia-
tion in the nature of carboxylate group attached to
arsenic. Unlike antimony(III) derivatives, (C6F5)3As
derivatives are not very good antimicrobial agents
and it would be reasonable to assume that the in-
troduction of pentafluorophenyl group probably re-
duces the toxicity of arsenic moiety.
[22] Raj, P.; Hussain, I.; Singhal, K. Arzneim-Forsch Drug
Res 1994, 44(I)-2, 178–181.
[23] Stokes, E. J.; Ridgway, G. L. (Eds.). Clinical Bacteri-
ology, 5th ed.; Edward Arnold Publisher; Baltimore,
MD, 1980, pp. 205–207.
[24] Verma, R. S.; Imam, S. A. Ind J Microbiol 1973, 13,
43–45.
[25] Van´de Loosdrecht, A. A.; Beelen, R. H.; Ossenkop-
pele, G. J.; Broekhoven, M. G.; Langenhuijsen, M. M.
J Immunol Methods 1994, 174(1–2), 311–320.
ACKNOWLEDGMENTS
The authors are grateful to National Botanical
Research Institute, Lucknow, India, for measuring
biological activity of compounds, and Regional So-
phisticated Instrumentation Centre, Central Drug
Research Institute, Lucknow, India, for microana-
lytical and spectral data.
Heteroatom Chemistry DOI 10.1002/hc